MICA: Dementias Platform UK 2 - Integrated Dementia Experimental Medicine
Lead Research Organisation:
University of Oxford
Department Name: Psychiatry
Abstract
DPUK is a public-private partnership to accelerate the development of new treatments for dementia. Since inception (2014) DPUK has increased the UK capacity for dementia research through infrastructure development and strategic data collection, leveraging a further £74.4m for dementia research.
The second phase of DPUK (DPUK2) focuses on developing UK capacity for dementia experimental medicine. A major challenge in developing new treatments is understanding the mechanisms through which a drug might operate. This involves precision studies where individuals of known vulnerability to specific causes of dementia are recruited to studies of cause-specific mechanistic pathways. These studies are very difficult to do as they require detailed assessment of volunteers before the study begins and standardising all the procedures in centres across the UK. These studies are also high risk in that there is no guarantee of success.
DPUK2 addresses these issues head-on at two levels. First it uses the UK's rich legacy in population cohort studies to identify suitable volunteers by using and enhancing existing cohort data. Second it creates a pre-competitive environment that brings together industry, academic and third-sector entities into partnership. This not only shares the costs and risks of experimental medicine (EM) studies, it also shares the benefits amongst a wider spread of stakeholders, each able to exploit the findings. DPUK2 does this through 3 inter-dependent work-streams.
1. The Data Portal (DP): The DP is a world leading end-to-end dementia focused data management solution. It enables large and complex datasets to be accessed remotely from around the globe without compromising data security. The DP is being developed in partnership with Health Data Research UK (HDR UK) so that we can maximise the data available to dementia research. The DP is used to manage all the data and information systems necessary for conducting precision studies. It brings large and complex datasets together in order to test new ideas; it manages personal information securely to enable recruitment to precision studies; it manages many types of data so that genetics, brain imaging, cognitive performance; and questionnaire data can all be analysed together.
2. The Trials Delivery Framework (TDF): The TDF is the vehicle that enables the DPUK2 experimental medicine programme to be efficient. The TDF organises our Clinical Studies Register (CSR) through which cohort members can volunteer for experimental medicine studies. The CSR allows us to contact members to enrich their data in terms of background information, cognitive testing, and where necessary genetics. As part of the CSR, and in partnership with the Alzheimer's Society, we have a PPI programme to understand what best practice is in terms if recruitment to experimental medicine studies. The TDF also enables us to identify centres of excellence across the UK for conducting experimental studies rigorously. This not only assures data quality, but also means that volunteers do not have to travel too far to participate.
3. The EM Incubator: The incubator is where our partners meet to plan and execute the experimental medicine programme. It has three themes; the first is Vascular Health. This is important because so many factors that affect the heart also affect the brain. If any area is likely to have drugs that already exist and could be re-purposed for dementia, this is it.The second theme is Synaptic Health. Here we investigate factors that affect the loss of neuron synapses. This is important because unlike neurons, synapses (the connections between neurons), can be generated, which is critical to learning and maintaining memory. The third area is Neuroimmunology. This is important as inflammation is a systemic problem that is known to affect the brain and might have systemic solutions, and so represents a promising area for new treatments.
The second phase of DPUK (DPUK2) focuses on developing UK capacity for dementia experimental medicine. A major challenge in developing new treatments is understanding the mechanisms through which a drug might operate. This involves precision studies where individuals of known vulnerability to specific causes of dementia are recruited to studies of cause-specific mechanistic pathways. These studies are very difficult to do as they require detailed assessment of volunteers before the study begins and standardising all the procedures in centres across the UK. These studies are also high risk in that there is no guarantee of success.
DPUK2 addresses these issues head-on at two levels. First it uses the UK's rich legacy in population cohort studies to identify suitable volunteers by using and enhancing existing cohort data. Second it creates a pre-competitive environment that brings together industry, academic and third-sector entities into partnership. This not only shares the costs and risks of experimental medicine (EM) studies, it also shares the benefits amongst a wider spread of stakeholders, each able to exploit the findings. DPUK2 does this through 3 inter-dependent work-streams.
1. The Data Portal (DP): The DP is a world leading end-to-end dementia focused data management solution. It enables large and complex datasets to be accessed remotely from around the globe without compromising data security. The DP is being developed in partnership with Health Data Research UK (HDR UK) so that we can maximise the data available to dementia research. The DP is used to manage all the data and information systems necessary for conducting precision studies. It brings large and complex datasets together in order to test new ideas; it manages personal information securely to enable recruitment to precision studies; it manages many types of data so that genetics, brain imaging, cognitive performance; and questionnaire data can all be analysed together.
2. The Trials Delivery Framework (TDF): The TDF is the vehicle that enables the DPUK2 experimental medicine programme to be efficient. The TDF organises our Clinical Studies Register (CSR) through which cohort members can volunteer for experimental medicine studies. The CSR allows us to contact members to enrich their data in terms of background information, cognitive testing, and where necessary genetics. As part of the CSR, and in partnership with the Alzheimer's Society, we have a PPI programme to understand what best practice is in terms if recruitment to experimental medicine studies. The TDF also enables us to identify centres of excellence across the UK for conducting experimental studies rigorously. This not only assures data quality, but also means that volunteers do not have to travel too far to participate.
3. The EM Incubator: The incubator is where our partners meet to plan and execute the experimental medicine programme. It has three themes; the first is Vascular Health. This is important because so many factors that affect the heart also affect the brain. If any area is likely to have drugs that already exist and could be re-purposed for dementia, this is it.The second theme is Synaptic Health. Here we investigate factors that affect the loss of neuron synapses. This is important because unlike neurons, synapses (the connections between neurons), can be generated, which is critical to learning and maintaining memory. The third area is Neuroimmunology. This is important as inflammation is a systemic problem that is known to affect the brain and might have systemic solutions, and so represents a promising area for new treatments.
Technical Summary
The objectives of the Dementias Platform UK renewal (DPUK2) are to:
1. Increase the precision of experimental medicine (EM) through precision phenotyping according to genetic risk
2. Increase the capacity of EM through streamlined systems and integrated informatics
3. Increase the opportunity for EM through agile and adaptive global partnerships
These will be achieved through three inter-dependent workstreams comprising:
1. Workstream A The Data Portal: The Data Portal will be enhanced to provide secure and auditable data management with an on-premise cloud, and hybrid solutions for :
- Observational and EM multi-modal data discovery
- In silico experiments including multi-modal and machine learning analysis
- Enriched phenotyping for the Clinical Studies Register
- Knowledge development and preservation
2. Workstream B The Trials Delivery Framework (TDF): The TDF will provide a recruitment and study delivery mechanisms for dementia experimental medicine:
- Pre-clinical recruitment via the Clinical Studies Register
- Early disease recruitment via existing NIHR and NHS investments (Join Dementia Research, BRCs, memory clinics)
- Trial delivery centre network drawn from existing structures including the DPUK imaging network, EPAD and NIHR TRC-D and BRCs.
3. Workstream C The EM Incubator: The EM incubator nurtures academic-industry partnerships for precision mechanistic EM studies, demonstrating the value of this approach through a series of pump-prime funded experiments on:
WP 5- Vascular Health
WP 6- Synaptic Health
WP 7- Neuroimmunology
DPUK2 aims to develop its EM portfolio according to scientific interest and further funding.
1. Increase the precision of experimental medicine (EM) through precision phenotyping according to genetic risk
2. Increase the capacity of EM through streamlined systems and integrated informatics
3. Increase the opportunity for EM through agile and adaptive global partnerships
These will be achieved through three inter-dependent workstreams comprising:
1. Workstream A The Data Portal: The Data Portal will be enhanced to provide secure and auditable data management with an on-premise cloud, and hybrid solutions for :
- Observational and EM multi-modal data discovery
- In silico experiments including multi-modal and machine learning analysis
- Enriched phenotyping for the Clinical Studies Register
- Knowledge development and preservation
2. Workstream B The Trials Delivery Framework (TDF): The TDF will provide a recruitment and study delivery mechanisms for dementia experimental medicine:
- Pre-clinical recruitment via the Clinical Studies Register
- Early disease recruitment via existing NIHR and NHS investments (Join Dementia Research, BRCs, memory clinics)
- Trial delivery centre network drawn from existing structures including the DPUK imaging network, EPAD and NIHR TRC-D and BRCs.
3. Workstream C The EM Incubator: The EM incubator nurtures academic-industry partnerships for precision mechanistic EM studies, demonstrating the value of this approach through a series of pump-prime funded experiments on:
WP 5- Vascular Health
WP 6- Synaptic Health
WP 7- Neuroimmunology
DPUK2 aims to develop its EM portfolio according to scientific interest and further funding.
Planned Impact
The main aim of DPUK2 is to use precision experimental medicine (EM) to reduce the mechanistic uncertainty surrounding the discovery of new treatments for dementia. To achieve this we will bring together the essential stages of EM workstreams - vascular, synaptic health and neuroinflammation. With a clear focus on identifying appropriate biomarkers for treatment stratification, there will be many beneficiaries, including dementia patients, their families and the wider population upon which much of the economic burden falls. We outline the immediate areas of academic and non-academic impact for DPUK2:
Academic sector
The Data Portal is a key development in the open science agenda, offering increased opportunity and economies of scale and efficiency. Scientists around the world can access an exceptional breadth of data for rapid data discovery and hypothesis testing. Additionally the implementation of a single common data model across datasets offers researchers unprecedented resource savings in data preparation, and enhanced access for cross-cohort data analysis.
The trials delivery framework addresses the fragmented nature of dementia-related trials in the UK. By providing precision risk stratification and targeted recruitment to multi-centre studies, using a network of clinical research centres, the UK becomes more attractive for conducting rigorous, relevant, cutting-edge science. The EM Incubator offers an agile pre-competitive model for developing partnerships with industry. Benefits to academics include access to developing technologies and commercially strategic research questions.
Commercial and private sector
Precision EM, leading to the de-risking of trials, is of profound interest to molecular, cellular and systems neuroscientists working in industry to identify disease mechanisms and drug targets. DPUK2 will develop its existing profile of industry engagement and collaboration, and has appointed a lead (Declan Jones) for industry. Our strategy is based around active interaction and collaborative funding of proof of concept studies leading to larger programmes of work. Such direct engagement is necessary for meaningful translation of basic research findings. Our list of partners demonstrates the interest of industry in this model.
Public sector, policy and practice
We will continue working with other agencies in spearheading contemporary debate about neurodegenerative disease and dementia. We have appointed a lead (Carol Routledge) for the charity and philanthropy sector who has in-depth contact with UK dementia policy makers, and our partnerships include ARUK and the Alzheimer's Society (the two main UK dementia research charities). More widely we contribute to the NIHR Dementia Progress Group, setting the Dementia 2025 priorities, and to UKRI cohort data management policy discussions - the Data Portal being a key demonstration of the challenges and benefits of policy development in this area.
Public engagement
Engagement and consultation with the public, patients and carers is central to our mission. This shapes how we communicate our research findings and also how we address such issues as stigma, research relevance and the research culture within the NHS in relation to dementia. We are committed to this because neurodegeneration should be regarded as increasingly tractable to research in genetics, neuroscience, and epidemiology, and that EM is key to future progress. We will therefore promote dementia research focusing on the understanding of pathogenesis and pathophysiology, and developing new approaches to treatment.
Skills and training
We will continue to recruit and train staff and students from a wide variety of backgrounds in inter-disciplinary skills that will be widely relevant outside academia. Moreover, through our multi-disciplinary approach we will be training a new cadre of early career researchers who will be attracted to, and equipped for, careers in dementia research
Academic sector
The Data Portal is a key development in the open science agenda, offering increased opportunity and economies of scale and efficiency. Scientists around the world can access an exceptional breadth of data for rapid data discovery and hypothesis testing. Additionally the implementation of a single common data model across datasets offers researchers unprecedented resource savings in data preparation, and enhanced access for cross-cohort data analysis.
The trials delivery framework addresses the fragmented nature of dementia-related trials in the UK. By providing precision risk stratification and targeted recruitment to multi-centre studies, using a network of clinical research centres, the UK becomes more attractive for conducting rigorous, relevant, cutting-edge science. The EM Incubator offers an agile pre-competitive model for developing partnerships with industry. Benefits to academics include access to developing technologies and commercially strategic research questions.
Commercial and private sector
Precision EM, leading to the de-risking of trials, is of profound interest to molecular, cellular and systems neuroscientists working in industry to identify disease mechanisms and drug targets. DPUK2 will develop its existing profile of industry engagement and collaboration, and has appointed a lead (Declan Jones) for industry. Our strategy is based around active interaction and collaborative funding of proof of concept studies leading to larger programmes of work. Such direct engagement is necessary for meaningful translation of basic research findings. Our list of partners demonstrates the interest of industry in this model.
Public sector, policy and practice
We will continue working with other agencies in spearheading contemporary debate about neurodegenerative disease and dementia. We have appointed a lead (Carol Routledge) for the charity and philanthropy sector who has in-depth contact with UK dementia policy makers, and our partnerships include ARUK and the Alzheimer's Society (the two main UK dementia research charities). More widely we contribute to the NIHR Dementia Progress Group, setting the Dementia 2025 priorities, and to UKRI cohort data management policy discussions - the Data Portal being a key demonstration of the challenges and benefits of policy development in this area.
Public engagement
Engagement and consultation with the public, patients and carers is central to our mission. This shapes how we communicate our research findings and also how we address such issues as stigma, research relevance and the research culture within the NHS in relation to dementia. We are committed to this because neurodegeneration should be regarded as increasingly tractable to research in genetics, neuroscience, and epidemiology, and that EM is key to future progress. We will therefore promote dementia research focusing on the understanding of pathogenesis and pathophysiology, and developing new approaches to treatment.
Skills and training
We will continue to recruit and train staff and students from a wide variety of backgrounds in inter-disciplinary skills that will be widely relevant outside academia. Moreover, through our multi-disciplinary approach we will be training a new cadre of early career researchers who will be attracted to, and equipped for, careers in dementia research
Organisations
- University of Oxford (Lead Research Organisation)
- European Bank for induced pluripotent Stem Cells (Collaboration)
- Catalan Health Institute (ICS) (Collaboration)
- University of Liege (Collaboration)
- Global Alzheimer's Platform Foundation (Collaboration)
- Eisai Ltd (Collaboration)
- EMBL European Bioinformatics Institute (EMBL - EBI) (Collaboration)
- Cardiff University (Collaboration)
- Stanford University (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- University of Bristol (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- National Institute for Health Research (Collaboration)
- IMI Europe Limited (Collaboration)
- Syracuse University (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- University of California, Irvine (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- University of Leuven (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- BrainDTech SpA (Project Partner)
- GlaxoSmithKline (United Kingdom) (Project Partner)
- Autifony Therapeutics (United Kingdom) (Project Partner)
- Eli Lilly (United Kingdom) (Project Partner)
- Alzheimer's Society (Project Partner)
- Cambridge Cognition (United Kingdom) (Project Partner)
- Gates Ventures, LLC. (Project Partner)
- Cognetivity Ltd (Project Partner)
- CytOx Limited (Project Partner)
- Alzheimer’s Research UK (Project Partner)
- AstraZeneca (United Kingdom) (Project Partner)
- IXICO Technologies Ltd (Project Partner)
- Janssen (United States) (Project Partner)
- UCB Pharma (Belgium) (Project Partner)
- Rodin Therapeutics (United States) (Project Partner)
Publications
Torabi F
(2024)
A common framework for health data governance standards
in Nature Medicine
Irizar P
(2023)
A comparison of probable post-traumatic stress disorder and alcohol consumption among active female members of the UK Police Service and UK Armed Forces.
in Social psychiatry and psychiatric epidemiology
Wills C
(2021)
A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients
in European Journal of Cancer
Mank A
(2022)
A longitudinal study on quality of life along the spectrum of Alzheimer's disease.
in Alzheimer's research & therapy
Ma S
(2023)
A Machine Learning Analysis of Big Metabolomics Data for Classifying Depression: Model Development and Validation.
in Biological psychiatry
Sri S
(2023)
A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia
in Cerebral Circulation - Cognition and Behavior
Vaghari D
(2022)
A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset.
in NeuroImage
Rouse MA
(2024)
A neuroanatomical and cognitive model of impaired social behaviour in frontotemporal dementia.
in Brain : a journal of neurology
Description | Contribution to UK Government's Neurodegeneration Initiative discussions - December 2021 and January 2022 |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
URL | https://www.gov.uk/government/news/government-to-invest-375-million-in-neurodegenerative-disease-res... |
Description | "UK DRI IPSC platform to model Alzheimer's disease risk (IPMAR) " |
Amount | £1,866,149 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2021 |
End | 07/2023 |
Description | Biopsychosocial determinants of cognitive and biomarker trajectories in preclinical Alzheimer's disease: Proposing a risk profiling tool for brain health |
Amount | £100,360 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2023 |
End | 09/2027 |
Description | Centre for Ageing and Dementia Research (CADR) |
Amount | £386,341 (GBP) |
Organisation | Welsh Assembly |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | Early-onset depression: Characterising development and identifying risks |
Amount | £763,680 (GBP) |
Funding ID | MR/R004609/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2017 |
End | 11/2020 |
Description | Genetics collaboration with Prof Bart De Strooper UK DRI programme |
Amount | £50,000 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2021 |
End | 04/2022 |
Description | Global Mental Health Impact of the Covid-19 Pandemic |
Amount | $150,000 (USD) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 10/2021 |
Description | Global Mental Health Impact of the Covid-19 Pandemic - LMIC focus |
Amount | $42,900 (USD) |
Organisation | National Institutes of Health (NIH) |
Sector | Public |
Country | United States |
Start | 06/2023 |
End | 06/2024 |
Description | Hearing aid use and dementia: Reviewing difficulties and barriers for users and non-users. |
Amount | £4,963 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 12/2022 |
Description | Identifying genetic biomarkers of survival for bowel cancer to aid patient management |
Amount | £90,000 (GBP) |
Organisation | Tenovus Cancer Care |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2019 |
End | 09/2022 |
Description | Knowledge Exchange (KE) Seed Fund 2022 |
Amount | £4,825 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2022 |
End | 09/2022 |
Description | Leveraging human genetics to identify target populations for dementia therapeutics (Eisai/DRI), project grant |
Amount | £200,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2020 |
End | 02/2023 |
Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
Amount | £48,502 (GBP) |
Organisation | Baily Thomas Charitable Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 10/2020 |
Description | Pilot study to develop an instrument to capture broad-ranging neurodevelopmental problems in children with a genetic diagnosis of intellectual disability |
Amount | £48,502 (GBP) |
Organisation | Baily Thomas Charitable Fund |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2019 |
End | 10/2020 |
Description | Pippa Watson, Clarendon Fund & Dept of Psychiatry Studentship. Project title: An investigation into the role of lifestyle factors in early, mid, and later life in SuperAgers |
Amount | £90,000 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2023 |
End | 09/2026 |
Description | Polygenic risk scores for neurodegeneration and Alzheimer's pathophysiology |
Amount | £951 (GBP) |
Organisation | UK Dementia Research Institute |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2020 |
End | 11/2021 |
Description | Profiling post-translational modifications of histone proteins as a determinant of Parkinson's susceptibility |
Amount | £232,404 (GBP) |
Funding ID | G-1502 |
Organisation | Parkinson's UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2016 |
End | 07/2018 |
Description | Software Sustainability Institute Fellowship (awardee: Dr Gaurav V Bhalerao) |
Amount | £3,000 (GBP) |
Organisation | Software Sustainability Institute |
Sector | Public |
Country | United Kingdom |
Start | 01/2023 |
Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
Amount | £310,234 (GBP) |
Funding ID | 209176 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2018 |
End | 06/2022 |
Description | Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders |
Amount | £310,234 (GBP) |
Funding ID | Judith Allardyce |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2018 |
End | 12/2021 |
Description | TRanslating Individual Alzheimer GEnetic risk into disease phenotypes [TRIAGE] |
Amount | € 420,000 (EUR) |
Organisation | JPND Research |
Sector | Academic/University |
Country | Global |
Start | 04/2020 |
End | 04/2023 |
Description | The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects |
Amount | £288,555 (GBP) |
Funding ID | 104210 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 02/2020 |
Description | Validating prognostic biomarkers for colorectal cancer and determining their clinical utility |
Amount | £155,801 (GBP) |
Organisation | Cancer Research Wales |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2018 |
End | 10/2021 |
Description | Your Beautiful Brain: Empowering Afro-Caribbean communities to support dementia research |
Amount | £22,646 (GBP) |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2023 |
End | 04/2023 |
Description | Your Beautiful Brain: Empowering Afro-Caribbean communities to support dementia research (Inspire Fund, ARUK) - Bauermeister et al. |
Amount | £22,646 (GBP) |
Funding ID | ARUK-IF2021-017 |
Organisation | Alzheimer's Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2022 |
End | 12/2022 |
Title | Alzhemer's Disease Polygenic Risk Profiling |
Description | This model used data from the powerful dataset comprising 17 008 cases and 37 154 controls obtained from the International Genomics of Alzheimer's Project (IGAP). Alzheimer's disease (AD) Polygenic risk scores were generated for 3177 cases and 7277 controls (GERAD data) and tested whether the alleles identified to associate with disease in IGAP sample are significantly enriched in the cases relative to the controls in the GERAD sample. The disease prediction accuracy was investigated in a sample of 3049 cases and 1554 controls (for whom APOE genotype data was available) by means of sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and positive and negative predictive values. The best prediction accuracy AUC = 78.2% (95% confidence interval 77-80%) was achieved by a logistic regression model with APOE, the polygenic score, sex and age as predictors. |
Type Of Material | Computer model/algorithm |
Year Produced | 2016 |
Provided To Others? | Yes |
Impact | This approach is used to create SNP arrays for AD prediction (for research only so far). |
Description | BRACE |
Organisation | University of Bristol |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | advice and training on genomic data analysis |
Collaborator Contribution | Investigating the genetic overlap between AD and other diseases or traits using polygenic risk scores in Avon Longitudinal Study of Parents and Children (ALSPAC) |
Impact | 1. Application of newly developed methodology (MR-Base), which hallows to do rapid high-throughput analysis of potentially interesting traits and environmental exposures. 2. Test for shared genetic susceptibility between AD and early life lipid levels, glycaemic, anthropometric, behavioral and cognitive traits in ALSPAC children |
Start Year | 2016 |
Description | Collaboration with Eisai AiM Institute |
Organisation | Eisai Ltd |
Department | Eisai Inc |
Country | United States |
Sector | Private |
PI Contribution | Consultancy on Polygenic risk score for clinical trials |
Collaborator Contribution | We are in the process of negotiations |
Impact | potentially this collaboration will pay for a time of a postdoctoral researcher |
Start Year | 2018 |
Description | Collaboration with European Bioinformatics institute |
Organisation | EMBL European Bioinformatics Institute (EMBL - EBI) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We plan to provide a software for polygenic risk score calculation and prosess the GWAS summary statistics for all current GWASes available in EBI GWAS catalogue |
Collaborator Contribution | provide data access to the GWAS catalogue |
Impact | This collaboration will provide the GWAS processed data to the research community for quick and efficient calculation of polygenic risk score for any disorder (stored in the EBI GWAS catalogue) |
Start Year | 2019 |
Description | DPUK |
Organisation | Medical Research Council (MRC) |
Country | United Kingdom |
Sector | Public |
PI Contribution | Steering Group member, DPUK work package lead. |
Collaborator Contribution | Creating Dementia Platform UK Data Portal |
Impact | In the process of creating on-line database with dementia cohorts, available in the UK and pipelines for data analyses. Multidisceplinary: genetics, bioinfirmatics, IT. |
Start Year | 2014 |
Description | DPUK-2 (2020 - 2023) |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Calculation of pathway specific PRS, relevant to the Neuroinflammation work package. |
Collaborator Contribution | Access to the DPUK cohorts |
Impact | data access to DPUK cohorts |
Start Year | 2020 |
Description | EISAI |
Organisation | Eisai Ltd |
Department | Eisai Europe Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | we provide expertise and data analysis of pathways and gene networks related to neurodegeneration |
Collaborator Contribution | The partner provide expertise the the biological definition of neurodegenerative gene networks |
Impact | NA |
Start Year | 2019 |
Description | GR@CE |
Organisation | Catalan Health Institute (ICS) |
Country | Spain |
Sector | Public |
PI Contribution | we analyse the genome-wide data |
Collaborator Contribution | the collaborators provided the data to us |
Impact | it is a multidisciplinary collaboration, involve clinicians, biologists and bioinformaticians |
Start Year | 2020 |
Description | GWAIS |
Organisation | University of Liege |
Country | Belgium |
Sector | Academic/University |
PI Contribution | We bring our expertise in AI and ML |
Collaborator Contribution | Collaborators bring their expertise in genetic interaction analyses. |
Impact | It is a multidisciplinary collaboration involving mathematicians, software developers and bioinformaticians |
Start Year | 2021 |
Description | Global Alzheimer's Platform (GAP) |
Organisation | Global Alzheimer's Platform Foundation |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | Development of processes to enable incorporation of the DPUK Trial Delivery Framework into a GAP European network |
Collaborator Contribution | Development of a GAP European network |
Impact | None |
Start Year | 2021 |
Description | Harvard University |
Organisation | Harvard University |
Department | Harvard Medical School |
Country | United States |
Sector | Academic/University |
PI Contribution | generation of polygenic risk scores |
Collaborator Contribution | provision of tissue samples and genotyped data |
Impact | none yet |
Start Year | 2019 |
Description | Innovate UK |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Consultancy |
Collaborator Contribution | Design of Alzhemer's disease chip |
Impact | In the process of designing of Alzhemer's disease SNP array. Multidisceplinary: medical genetics, bioinformatics, statistics |
Start Year | 2015 |
Description | Join Dementia Research and Great Minds |
Organisation | National Institute for Health Research |
Department | NIHR Join Dementia Research |
Country | United Kingdom |
Sector | Public |
PI Contribution | Developing the processes to incorporate Join Dementia Research volunteers into the Great Minds register, providing information on the Great Minds Register, promoting the use of Join Dementia Research on websites and at public events, updating the Join Dementia Research database for volunteers that have joined the Great Minds register. |
Collaborator Contribution | Developing the Join Dementia Research platform to enable links to the Great Minds register, promoting Great Minds as a collaborator organisation of Join Dementia Research. |
Impact | Over 1,500 Join Dementia Research volunteers have joined the Great Minds register |
Start Year | 2021 |
Description | Leuven University |
Organisation | University of Leuven |
Country | Belgium |
Sector | Academic/University |
PI Contribution | generation of polygenic risk scores |
Collaborator Contribution | sharing genotyped data and PRS |
Impact | none yet |
Start Year | 2018 |
Description | MRC fellowship |
Organisation | University of Bristol |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | advice and training on genomic data analysis |
Collaborator Contribution | A researcher, Dr. Emma Anderson, who is a highly productive junior researcher |
Impact | 1. To improve causal inference in mendelian randomization studies of dementia 2. To improve understanding of the genetic risk for dementia and trajectories of cognitive capabilities in aging 3. To identify modifiable risk factors that are related to dementia and cognitive decline |
Start Year | 2016 |
Description | NEURO Cohort |
Organisation | IMI Europe Limited |
Country | United Kingdom |
Sector | Public |
PI Contribution | Development of processes to hold and share data across European sites |
Collaborator Contribution | Development of technical processes, data model and a synthetic dataset |
Impact | None |
Start Year | 2021 |
Description | Stanford University |
Organisation | Stanford University |
Country | United States |
Sector | Academic/University |
PI Contribution | generation of polygenic risk scores |
Collaborator Contribution | sharing genotyped data and PRS |
Impact | none yet |
Start Year | 2019 |
Description | Syracuse University |
Organisation | Syracuse University |
Country | United States |
Sector | Academic/University |
PI Contribution | still under negotiation |
Collaborator Contribution | data analysis consultancy |
Impact | none yet |
Start Year | 2019 |
Description | Tissue Discovery Platform and EBiSC |
Organisation | European Bank for induced pluripotent Stem Cells |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Development of processes to enable provision of access to induced pluripotent stem cells and associated phenotypic data |
Collaborator Contribution | Storage of induced pluripotent stem cells, contribution of phenotypic data, development of polygenic risk scores |
Impact | None |
Start Year | 2021 |
Description | UC Irvine |
Organisation | University of California, Irvine |
Country | United States |
Sector | Academic/University |
PI Contribution | generation of polygenic risk scores |
Collaborator Contribution | sharing genotyped data and PRS |
Impact | none yet |
Start Year | 2019 |
Description | UK7T Network |
Organisation | Cardiff University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Description | UK7T Network |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Description | UK7T Network |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Description | UK7T Network |
Organisation | University of Glasgow |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Description | UK7T Network |
Organisation | University of Nottingham |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Description | UK7T Network |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
Start Year | 2021 |
Title | Application management system |
Description | The Application management system allows the progress of applications through the application process to be tracked. The creation of the system allows multiple team members to track an application and to action any issues. |
Type Of Technology | Webtool/Application |
Year Produced | 2021 |
Impact | The system allows DPUK to expand the application system across a team of people and creates greater visibility across the administrative team. this will streamline applications and allow DPUK to increase the number of projects that it can administer. |
Title | Effective |
Description | We have developed a novel approach to account for multiple testing in genome-wide association studies as published in (Moskvina and Schmidt, 2008). The software is C++ code, which can be compiled for any computational platform (Windows, Unix, Linux). |
Type Of Technology | Software |
Year Produced | 2008 |
Open Source License? | Yes |
Impact | The software was requested from the authors more than 10 times since the paper was published. We have made it now publicly available. |
URL | http://github.com/DRI-Cardiff/Keffective |
Title | POLARIS |
Description | We developed a novel approach to genetic set-based analysis and polygenic risk scoring, which accounts for linkage disequilibrium between SNPs and informs the analysis with previously reported effect sizes of a SNP's association to disease. We call this method POLARIS: POlygenic Linkage disequilibrium-Adjusted RIsk Score. |
Type Of Technology | Software |
Year Produced | 2017 |
Open Source License? | Yes |
Impact | NA |
URL | https://github.com/BakerEA/POLARIS |
Title | Project output tracking system |
Description | The project outputs system is a webform system that contacts researchers on a regular basis to ask for project outputs update. data entered into the forms populate a database. |
Type Of Technology | Webtool/Application |
Year Produced | 2021 |
Impact | The project outputs system allows DPUK to automate output collection from researchers and to create a database of ouputs. This database will then be used to feed automated dashboards that will allow DPUK to visually track outputs. |
Description | 21/01/2021 - Data Science and Population Health Research. University of British Columbia, Canada |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Data Science and Population Health Research. University of British Columbia, Canada, 21/01/21. |
Year(s) Of Engagement Activity | 2021 |
Description | A formal working group, expert panel or dialogue - DPUK Annual Conference 2018: The power of cohorts 23 April 2018 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Attended one-day conference on using DPUK platform. |
Year(s) Of Engagement Activity | 2018 |
Description | AAIC pre-conference workshop "Getting Started with Neuroimaging Analysis" August 2022, San Diego , USA (Dr Ludovica Griffanti) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Ludovica Griffanti co-organised the Alzheimer's Association International pre-conference workshop "Getting Started with Neuroimaging Analysis" August 2022 (San Diego, USA) Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) - Imaging Professional Interest Area (PIA). The workshop was well received and approved to be run again in 2023. |
Year(s) Of Engagement Activity | 2022 |
Description | ARUK Oxford Drug Discovery Institute |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited presenter at the ARUK Oxford Drug Discovery Institute (ODDI) Collaborators meeting |
Year(s) Of Engagement Activity | 2020 |
Description | ARUK Thames Valley Network Dementia Research Day presentation |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited talk on ECR training and conducting multi-cohort research on the DPUK Data Portal |
Year(s) Of Engagement Activity | 2022 |
Description | Alzheimer's Association International Conference San Diego USA poster |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Poster presentation: ADHD and cognitive change |
Year(s) Of Engagement Activity | 2022 |
Description | Alzheimer's Association International Conference San Diego USA presentation |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited oral Presentation: Facilitating Multi-modal research with the DPUK Data Portal |
Year(s) Of Engagement Activity | 2022 |
Description | Alzheimer's Research UK (ARUK) Thames Valley Network Dementia Day (1st July 2022, St Anne's college, Oxford) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Ludovica Griffanti co-organised the Alzheimer's Research UK (ARUK) Thames Valley Network Dementia Day and chaired panel discussion session. |
Year(s) Of Engagement Activity | 2022 |
Description | Amsterdam meeting at Alzheimer Center Amsterdam |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Prof John Gallacher was invited to the Alzheimer Center Amsterdam by the Amsterdam University Medical centre. Discussion were made around Biobanking and the fluid biomarker development with the potential to collaborate. |
Year(s) Of Engagement Activity | 2022 |
Description | An invited interview at the Alzheimer's Research UK (ARUK) 2019 the Video Journal of Dementia |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Media (as a channel to the public) |
Results and Impact | An interview for Video Journal of Dementia |
Year(s) Of Engagement Activity | 2019 |
URL | http://www.vjdementia.com |
Description | An invited interview on issues facing researchers in Brexit for the Cross Party Group on Medical Research for Alzheimer's Society, UK |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Have provided an opinion on issues facing researchers in Brexit for the Cross Party Group in the Welsh Assembly looking at Medical Research |
Year(s) Of Engagement Activity | 2018 |
Description | BBC Radio Berkshire interview on project 'Your Beautiful Brain' |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interview regarding my 'Your Beautiful Brain' art workshops for Black African and Caribbean communities |
Year(s) Of Engagement Activity | 2023 |
Description | BBC Radio South interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interview regarding my 'Your Beautiful Brain' art workshops for Black African and Caribbean communities |
Year(s) Of Engagement Activity | 2022 |
Description | Biodiversity, Medicine, and Health workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | In this workshop we will explore critically important initiatives - based on botanical-garden and natural-history collections and databases - to build frameworks for extracting knowledge from collections and databases, as building-blocks for future new initiatives. This gives us the background to explore in the following sessions a range of examples in health and medicine. Nature has always been the primary source of novel molecules for drug development and remains the source of primary health care among millions of people worldwide. Much biomedical research relies on plants, animals, and microbes to better understand human physiology and to understand and treat human diseases. Loss of biological diversity of microorganisms, flora and fauna means losing, even before their discovery, many of nature's chemicals and genes of the kind that have already provided humankind with enormous health benefits. Meanwhile, revealing the untapped potential uses of natural products will strengthen the hand of those seeking to better protect the natural world. |
Year(s) Of Engagement Activity | 2022 |
Description | Brain Health Conference, Edinburgh 2022: "Harnessing the power of big data in the UK Biobank for brain health clinics" (Dr Ludovica Griffanti) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Ludovica Griffanti was invited to present at the Brain Health Conference, Edinburgh 2022: "Harnessing the power of big data in the UK Biobank for brain health clinics" , which sparked conversations and initiated potential collaborations. |
Year(s) Of Engagement Activity | 2022 |
Description | Brain Health Conference, Edinburgh 2022: "Oxford Brain Health Clinic and the Translational Research Collaboration for Dementia (TRC-D)" (Prof Clare Mackay) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Clare Mackay was invited to present at the Brain Health Conference, Edinburgh 2022: "Oxford Brain Health Clinic and the Translational Research Collaboration for Dementia (TRC-D)", which sparked discussions and potential collaborations. |
Year(s) Of Engagement Activity | 2022 |
Description | CINECA/H3BioNet Harmonisation Event |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture: Harmonisation and standardisation of large cohort datasets |
Year(s) Of Engagement Activity | 2022 |
Description | Cognitive testing of older adults with ADHD and dyslexia |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Presented at the DPUK conference on 2 March 2023 Authors: Elen Golightly, Emma Squires, Sarah Bauermeister Introduction: Neurodiverse conditions such as Attention Deficit Hyperactivity Disorder (ADHD), Autistic Spectrum Disorder (ASD), and dyslexia may mirror selective symptoms found in dementia and mild cognitive impairment (MCI), including cognitive impairment, memory issues and executive dysfunction. Reaction time variability (RTV) as a measure of a cognitive reaction time variability within a single task is known to be increased for adults with dementia and MCI (Bauermeister & Bunce, 2015). Likewise, neurodiverse conditions, are similarly associated with increased RTV. The aim of this study was to investigate the effect of neurodiverse conditions on cognition (RTV). Methods: We conducted our analysis on the Dementias Platform UK (DPUK) Data Portal using Brain Health Registry (BHR) data, n=38,929 (M=58.76, SD=13.20 years at baseline). We constructed a longitudinal Structural Equation Model investigating the effect of ADHD and dyslexia on cognitive RTV, controlling for baseline age and education. The model included three waves of RTV results as the tasks were repeated over 5 years. The model was repeated for all four cognitive tasks: DET, IDN, OCL and ONB. Approximately 1500 participants have a past and/or current ADHD diagnosis and approximately 1700 have diagnosis of dyslexia or reading disorder. Results: For each task performed at baseline we find RTV increases for people with ADHD (ß=0.004-0.007, p<0.01) and dyslexia, (ß=0.004-0.006, p<0.01). However, when the tasks were repeated, the associations between neurodiversity and RTV were no longer significant after controlling for baseline. Conclusion: While neurodiverse conditions appear to have an initial deleterious effect on RTV, we find little evidence for significant longitudinal increase in RTV from having a neurodiverse condition. We conclude that when conducting cognitive tests on older adults, it is important to take into account the impact neurodiverse conditions may have that might lead to a result similar to what is expected for a patient with dementia or MCI. |
Year(s) Of Engagement Activity | 2022 |
Description | Comment on the Polygenic Hazard scores for AD study by Tan et al (2019), Brain 142; 460-470 for Alzforum |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | I have commented on a study which was covered on Alzforum about polygenic hazard scores for AD, and shared my opinion on their availability to the public. |
Year(s) Of Engagement Activity | 2019 |
URL | https://www.alzforum.org/news/research-news/multi-gene-score-predicts-cognitive-decline-independentl... |
Description | DEMON Network - Using the DPUK Remote Data Platform |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As the Director of Dementias Platform UK, Prof John Gallacher was invited to give a talk introducing DPUK and the Remote Data Platform, demonstration on the DPUK Data Portal including logistics, cohort identification, data discovery and variable selection. |
Year(s) Of Engagement Activity | 2022 |
Description | DEMON Network Summit 2022: AI for Precision Dementia Medicine |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The DEMON Network Summit 2022 on AI for Precision Dementia Medicine will be held at the Royal Society in London on the 13th and 14th of June 2022. This invitation-only event is funded by the Alan Turing Institute and Alzheimer's Research UK, and is delivered in partnership with the UK Dementia Research Institute. The Summit, attended by world-leading scientists, clinicians, funders and industry, is based around a series of exciting debates exploring some of the most contentious issues we face. On day two we will run two interactive workshops to discuss what practical changes need to be made to the research landscape to enhance experimental medicine and digital innovation. We would like to invite you to day two of the Summit (14th June) given your role at DPUK, as the focus will be on capacity building and fuelling innovation. We are able to cover your travel and accommodation costs to attend if required, and we are also delighted to invite you to a drinks reception and dinner on the evening of the 13th of June. |
Year(s) Of Engagement Activity | 2022 |
URL | https://demonsummit2022.com/ |
Description | DEMON/DPUK workshop |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Co-Organiser and speaker: Using the DPUK Data Portal for cross-cohort research |
Year(s) Of Engagement Activity | 2022 |
Description | DPUK Autumn Academy 2022 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | DPUK's Autumn Academy is an annual, week-long series of online presentations, lectures and guided tutorials aimed at helping researchers enhance their data science skillsets. Our next event will be held from Monday 21 to Friday 25 November 2022 and will focus on the theme of longitudinal methods. The Autumn Academy is aimed at experienced data analysts who are seeking to expand their repertoire of cohort analysis techniques. Participants work with cohort data in the DPUK Data Portal to learn new skills and work on real research projects. The Data Portal is a dementia-optimised health research data repository featuring 60 cohorts and over 3.5 million individual participants. Each day of the event involves morning presentations and lectures on themed areas of dementia research and specific longitudinal cohort analysis techniques. Afternoon sessions allow participants to work on research projects using real-world data from cohorts in the DPUK Data Portal. Topics include: Longitudinal logistic and linear modelling, Cox regression and survival analysis, Structural equation modelling, Machine learning |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.dementiasplatform.uk/research-hub/data-analyst-training/dpuk-autumn-academy |
Description | DPUK C-SURV ontology IP meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As Director of Dementias Platform UK, Prof John Gallacher was invited to discuss intellectual property surrounding C-SURV. |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK LinkedIn channel |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | The DPUK LinkedIn channel now has 202 followers - more than twice as many as this time last year. We are also supporting a Vascular Health group aimed at engaging with industry. |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://www.linkedin.com/company/dpuk |
Description | DPUK Newsletter article: "In conversation: Postdoctoral researcher Gaurav Bhalerao talks about the significance of neuroimaging studies" |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | DPUK Newsletter article: "In conversation: Postdoctoral researcher Gaurav Bhalerao talks about the significance of neuroimaging studies" |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.dementiasplatform.uk/news-and-media/blog/in-conversation-postdoctoral-researcher-gaurav-... |
Description | DPUK Spring Academy |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | DPUK's all-new Spring Academy is an annual, week-long series of lectures, presentations and guided tutorials giving researchers an introduction to cohort data analysis techniques. The event ran virtually this year from 7-11 March 2022. Designed for students, researchers and professionals with little experience of analysing health or cohort data, the Spring Academy course provides an introduction to analysis techniques with a particular focus on dementia. Our expert line-up of presenters, lecturers and tutorial leaders explore topics including multi-modal analysis, multi-cohort projects, data standardisation, and linear models. DPUK's Spring Academy complements the Autumn Academy, which is aimed at more advanced analysts and which was held for the first time in 2021, and DPUK's Datathon series, which gives researchers the chance to work in multidisciplinary groups on real research projects in the DPUK Data Portal. Each day involves a morning contextual presentation and statistical lecture, with a guided analysis tutorial in the afternoon. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.dementiasplatform.uk/research-hub/data-analyst-training/dpuk-spring-academy |
Description | DPUK Translation |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Translation 2023 is part of a change to the landscape of dementia research. The conference is now sold out, but you can follow what is said at the conference using the hashtag #TRANSLATION2023. People from academia, industry, the third sector and government will be attending and hearing about the latest research in human experimental medicine for dementia. The challenge for dementia research is translating discoveries in the lab into experimental trials and on to therapies and new drugs quickly, at scale and using all available research channels. There will be discussions about exciting developments in big data, biomarkers and trials delivery - all of which can lead to new disease-modifying treatments for dementia. |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK Translation 2023 Conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited oral Presentation; Big data analytics using the DPUK Data Portal & Oral presentation |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK Translation 2023 Conference Session lead ECRs |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | ECR workshop |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK Twitter channel (@DementiasUK) |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | DPUK's Twitter channel has gone from strength to strength, passing 5,500 followers in February 2022 - an increase of over 1,000 on the previous year. The channel achieved an average of 74,500 impressions (people reached) per month throughout 2021. Engagement with the channel is strong, with material about research outputs and awareness days being particularly well received. |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://twitter.com/DementiasUK |
Description | DPUK Work Package Forum |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | All leads of the Work Packages under Dementias Platform UK had a meeting to present updates and discuss future strategy for DPUK. |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK YouTube channel |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | The DPUK YouTube channel hosts video content including: DPUK podcasts; our new animation; interviews with event participants; recordings of Great Minds members' events; featured cohorts; monthly research round-up videos. |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://www.youtube.com/channel/UC9OKgZG5Dq0RheCDV3upakw/ |
Description | DPUK and Deep and Frequent Phenotyping programme (DFP) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | As director of Dementias Platform UK, Prof John Gallacher was invited to a meeting with Deep and Frequent Phenotyping programme (DFP) on potential collaboration and connect to Cartography. |
Year(s) Of Engagement Activity | 2023 |
Description | DPUK blog |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | The DPUK blog features a range of articles on topics including: different types of dementia; new podcasts; aspects of dementia research; experiences of those in dementia research. The blog is written in a lay-friendly style with the aim of being accessible to wider audiences. Recent blog titles include: --Creutzfeldt-Jakob disease: a rapidly progressing form of dementia --International Day of Women and Girls in Science --Can dance help defend against dementia? --How has modern technology shaped dementia care? |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://www.dementiasplatform.uk/news-and-media/blog |
Description | DPUK blog post "DPUK researcher picks 'top 5' highlights of AAIC dementia research conference" (Dr Ludovica Griffanti) |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | After attending AAIC 2022, Ludovica Griffanti summarises the highlights of the conference to disseminate the latest news in dementia research through the DPUK blog. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.dementiasplatform.uk/news-and-media/blog/dpuk-researcher-picks-top-5-highlights-of-aaic-... |
Description | DPUK featured in new Alzheimer Europe report on data sharing - 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | he report, titled 'Data sharing in dementia research - the EU landscape', evaluates the legal and policy landscapes that dementia researchers have had to navigate in recent years, identifying key barriers and enablers for data sharing. In his preface to the document, Jean Georges, Executive Director of Alzheimer Europe, says: 'In our 2019 report, "Estimating the prevalence of dementia in Europe", we showed that the number of people with dementia in Europe is likely to double by 2050, increasing from 9,780,678 to 18,846,286 in the wider European region. However, despite its increasing incidence, and high health and social care cost, research on dementia receives a disproportionately low amount of funding compared to other disease areas. As a result, there is an urgent need to maximise the utility of data from dementia research. 'Data sharing represents an important step towards meeting this need, and could help increase our understanding of the causes, treatment, prevention and care of dementia. However, there is still much to do to improve data sharing in dementia research - in particular, for clinical studies, where data sharing is not yet common practice.' Writing in the report, DPUK's Director, Professor John Gallacher, describes how the DPUK Data Portal is 'democratising science'. He says: 'The DPUK Data Portal was developed in collaboration between the DPUK public-private partnership and research teams leading dementia cohort studies in the UK. As a data repository, the DPUK Data Portal facilitates access to data from over 3 million participants in studies such as Generation Scotland, LBC (Lothian Birth Cohort) 1936 and GERAD (Genetic and Environmental Risk in Alzheimer's Disease). Data from these cohorts cover a broad spectrum of variables, including genetic test results, brain imaging data and neuropsychological assessments of memory and brain function. Once access to data is approved, researchers are able to work with the curated data in a secure, remote-access environment, allowing them to develop new research questions and test or validate novel hypotheses on dementia. 'The DPUK Data Portal was built to democratise science. By providing remote access to data from 42 cohorts (n>3.4m) anyone, from Botwana to Brussels, can access some of the world's best data. All that's required is a good idea, internet connectivity, and an academic or industry email. Our data discovery tools and streamlined access procedures enable rapid access decisions (median time to decision: 23 days), with most datasets and most computational facilities, including analytical software, being free at point of use. Bona fide researchers work on approved projects within a secure and fully auditable multi-modal environment. Findings, but not data, may be exported for publication. 'Integrating imaging, genomic and health data is challenging, even for experts. So our datathon and summer school programme, targeting early-career researchers, is designed to introduce up-and-coming analysts to good data management and rigorous longitudinal analysis. 'In a spirit of collaboration, DPUK is working alongside data platforms around the world, including Dementias Platform Korea, Dementias Platform Australia, EMIF-AD, GAAIN, IALSA, SCAI, Cohen Veterans Bioscience, the Krembil Brain Institute, and ADDI, to create a global data alliance for dementia research.' |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.dementiasplatform.uk/news-and-media/latest-news/dpuk-featured-in-new-alzheimer-europe-re... |
Description | DPUK newsletter |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The DPUK newsletter goes out three times a year to a distribution list of around 450 DPUK stakeholders. It provides updates on DPUK developments, research outcomes, funding opportunities etc. it has an average open rate of around 31%, and a click-through rate of around 8%. |
Year(s) Of Engagement Activity | 2021,2022 |
Description | DPUK website news section |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The news section of the DPUK website features articles about new developments in DPUK and outcomes related to the DPUK programme. For example, recent stories have been titled: --People with both type-2 diabetes and high blood pressure have worse brain health than those with just one of these conditions --Study finds hearing aid use is linked to slower decline in thinking skills --New research suggests lowering brain cell excitability could help prevent Alzheimer's disease --DPUK receives funding to run four art workshops to improve diversity in dementia research |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://www.dementiasplatform.uk/news-and-media/latest-news |
Description | Data Science and Population Health : a Team Science Approach |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Data Science and Population Health : a Team Science Approach. Liverpool University MSc in Data Science lecture, 03/11/21. |
Year(s) Of Engagement Activity | 2021 |
Description | Data Science and Population Health Research |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Data Science and Population Health Research. University of British Columbia, Canada, 21/01/21 |
Year(s) Of Engagement Activity | 2021 |
Description | Dementia Research Oxford - Meeting with Daiichi Sankyo |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | This was a meeting to discuss the potential collaboration between Dementia Research Oxford and Daiichi. Daiichi are undergoing a strategic review of their neuroscience activities that will complete around year end. |
Year(s) Of Engagement Activity | 2022 |
Description | Dementia Research Oxford - Shionogi meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Prof John Gallacher gave a presentation on DPUK at a joint meeting with Shionogi Inc, a Pharma company from Japan as they are interested in developing collaborations with Oxford in the dementia space. |
Year(s) Of Engagement Activity | 2022 |
Description | Dementia Research Oxford seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Prof John Gallacher gave a presentation on Developments in dementia translation research with the Dementias Research Oxford. |
Year(s) Of Engagement Activity | 2022 |
Description | Dementia biomarker set for UK Biobank |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This meeting was proposed by Prof John Gallacher to convene a small working group to propose dementia/ageing related fluid biomarkers that might be assessed from UK Biobank samples. |
Year(s) Of Engagement Activity | 2022 |
Description | Dementias Platform UK (DPUK) International Scientific Advisory Board (ISAB) retreat |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | International Scientific Advisory Board (ISAB) retreat of Dementias Platform UK (DPUK) has gathered in-person in order to discuss future strategy of the platform. |
Year(s) Of Engagement Activity | 2023 |
Description | Dementias Platform UK Spring Academy March 2022. Talk: "Multi-modal dementia research" (Prof Clare Mackay) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Clare Mackay contributed to the Dementias Platform UK Spring Academy, a one-week training delivered by DPUK |
Year(s) Of Engagement Activity | 2022 |
Description | Dementias Platform UK Spring Academy, March 2022. Talk "Large brain imaging datasets: opportunities and challenges" (Dr Ludovica Griffanti) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Ludovica Griffanti contributed to the Dementias Platform UK Spring Academy, a one-week training delivered by DPUK |
Year(s) Of Engagement Activity | 2022 |
Description | Dept. Psychiatry talk on the DPUK Data Portal |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | University of Oxford Dept. Psychiatry BRC Research Ready Schools & Family Hubs Invited oral presentation; Data Discovery and Analysis using the DPUK Portal |
Year(s) Of Engagement Activity | 2023 |
Description | DiMe | Collaboration on a patient-centric research in ADRD |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | As the Director of Dementias Platform UK, Prof John Gallacher was invited to discuss potential collaboration between DiMe and Dementias Platform UK. |
Year(s) Of Engagement Activity | 2022 |
Description | Eisai Ltd webinar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Invited presenter at Eisai Ltd webinar |
Year(s) Of Engagement Activity | 2020 |
Description | Event - DPUK Autumn Academy - October 2021 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | DPUK's Autumn Academy was an annual, week-long series of presentations, lectures and workshops aimed at helping researchers enhance their data science skillset. The inaugural event (held from 27 September to 1 October 2021) focused on the theme of cohort data analysis. The Autumn Academy was aimed at experienced data analysts who are seeking to expand their repertoire of analysis techniques. Participants worked with cohort data in the DPUK Data Portal to learn new skills and work on real research projects. Each day involved morning presentations and lectures on themed areas of dementia research and specific cohort analysis techniques. Afternoon sessions allowed participants to work on research projects using real-world data from cohorts in the DPUK Data Portal. DPUK's Autumn Academy complements the Spring Academy, which is aimed at beginner analyst. 24 attendees (6 groups of 4 people) from across the globe attended virtually. The event received extremely positive feedback, with some saying 'Thanks to this academy, I have learned a lot about: available databases, multi-cohort and longitudinal analyses, and new research conducted or in progress on dementia and Parkinson's disease. This academy is a great resource for researchers.' 'There were some useful introductory lectures on several techniques that I have not been exposed before, such as machine learning and SEM. That was very informative.' 'A great update including developments in global data initiatives, the latest research on PD and dementia, the basis of different ontologies and projects and a great insight in several very useful new (to me) data analysis models to get to grips with that will bring an advantage to be able to apply in data analysis of DPUK projects. Also need to get on with learning Python! I learnt too how much the DPUK data portal is constantly evolving, building connections internationally with other dementia platforms and with adding training such as this academy, is arming researchers with a wider selection of the latest tools to apply where suitable to aid their dementia research. The questions raised by attendees showed the variety of analysis levels we had but also that we are all working in our various ways towards the same unifying goals.' |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.dementiasplatform.uk/research-hub/data-analyst-training/dpuk-autumn-academy |
Description | Event - DPUK Datathon March 2021 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | DPUK Datathons are a key part of DPUK's data analyst training programme, placing researchers in multidisciplinary teams to generate valuable new findings in dementia research. Attendees attended virtually and used cohort data in the DPUK Data Portal to explore a particular research question relating to dementia risk and progression. Around 15-30 hours of additional work beyond the formal workshops were required for research and collaboration. The event included expert introduction to selected population cohorts; four online cohort analysis workshops; support and guidance during offline periods; and potential for studies to develop into publications. Taking place on 1-12 March 2021, at this event 15 attendees (3 groups of 5 attendees) were asked to develop new studies relating to 'Co-morbidities in Cognitive Decline, including Cardiovascular Disease' . Attendees gained significant understanding on how to use the Data Portal for conducting their analyses. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.dementiasplatform.uk/research-hub/data-analyst-training |
Description | Expert Panel Member on Keynote Programme 'Driving Real World Patient Centricity' - Genesis In-Person Conference - London, 9Dec21 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Astrid Geeraert from Flanders Invest and Trade in London kindly passed me your details after we discussed your possible involvement in the Genesis conference session 'Driving Real World Patient Centricity' at 13.20 GMT on 9 December in London (1 Wimpole street). You can see the programme here. I am conscious you are already involved in the webinar session they organise on the 8 Dec, so just to clarify this panel suggestion would be for the main conference on 9 December in person. To give you some background, Genesis is One Nucleus annual London conference where we discuss the main trends that developed in our industry in the past year including deal activity, therapeutics and technology developments. This particular panel discussion should reflect on how the patient centricity approach claimed by pharma is translated in concrete actions, including more technology and data support, and the various considerations in terms of regulatory, interoperability, data protection it is bringing. I have 3 panelists confirmed who are Mark Avery, Eastern Academic Health Science Network (EAHSN) involved in a very interesting programme linking patient engagement and improved data collection and processing: the Gut reaction programme, Philippa Brown from AstraZeneca to provide the pharma perspective and Natalie Wilson from NIHR who works on decentralised trial design and patient engagement. I think that Dementia is very interesting area to discuss these aspects of 'how' engaging with patients who may not be patients yet as pre symptomatic but how crucial the data collection is at this stage and given your engagement in the UK biobank it would be extremely relevant to the conversation. Panelists: Mark Avery, EAHSN Phillippa Brown, AstraZeneca Natalie Wilson, NIHR Paresh Malhotra, Imperial College London John Gallacher, University of Oxford And I am really pleased that Mike Ward, Global Head of Thought Leadership has agreed to chair it as not only he is good in this role but also has a keen interest in the topic 2. Wherever they are situated in the ecosystem, what is the biggest challenge organizations, will face when attempting to establish a patient-centric culture, and how do you win over skeptics? 3. At which points in the medicines discovery, development and delivery timeline can the patient voice have a genuine and productive impact? Can you give real world examples of how the patient voice has made a real difference to plans at your organization? 4. How do you identify the patients who are going to be useful? How do you ensure that they are truly representative of people who matter? What challenges have you faced and how did you overcome them? 5. In this era of network connectivity and increased use of technology, what tools are you using or plan to use to be able to main a patient-centric trajectory? 6. Looking at how organizations can organize themselves are there any particular functions, activities or processes that are must-haves in order to be patient-centric? How can companies incentivise their employees to be patient-centric? 7. What does good patient-centricity look like and what metrics do you use to determine how well you are doing? 8. How easy is to identify the return on investment or other tangible benefits you can achieve by being patient-centric? 9. The development and delivery of medicines requires a whole ecosystem working well. While we have heard of the bilateral efforts of pharma and biotechs working with patients, what is being done to encourage other stakeholders, such as clinicians, regulators and health technology assessment agencies, to embrace patient-centricity? 10. Finally, what piece of advice would you give to others in the industry that might want to either introduce for the first time or enhance their patient-centricity efforts? |
Year(s) Of Engagement Activity | 2021 |
URL | http://www.genesisconference.com/keynote-programme-2021/ |
Description | Expert attendee at MND Collaborative Partnership workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Third sector organisations |
Results and Impact | The workshop will start the application process for a new funding initiative called the MND Collaborative Partnership, which has been established by a £4M commitment from the Funders. The Partnership aims to bring the research community together to tackle a major block to the translation of MND research. This is a unique and exciting opportunity for researchers to participate in an initiative that will drive MND research towards translation and lead to new treatments for MND. With significant advances in recent years delivering a better understanding of the MND disease aetiology, it is timely to address the blocks to translation. This is seen as a first step in advancing the research field toward the delivery of new treatments for patients with MND. The Funders aim to support one substantive collaborative application involving multiple institutions that brings together the strengths of the UK MND research field and leverages multidisciplinary expertise and resources in the wider research landscape (e.g. DPUK , UK DRI, HDRUK etc). The applicants will be required to work together to agree a cohesive set of work packages to be delivered and who will lead/deliver each of those. Further details of the call will be made available ahead of the workshop. The Aim of the Workshop • To launch the call and for the Funders to explain what they would like to achieve. • To describe the application process and post award requirements. • To discuss the MND research landscape and agree on the blocks to translation that could be feasibly addressed through a collaborative research effort supported by the Partnership. • Present the resources (e.g. skills, infrastructure etc) available to the Partnership - discuss and agree any gaps. • Discuss the process of development of the application, agree who will do what and begin assigning tasks |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.lifearc.org/funding/rare-disease-research-funding/mnd-collaborative-partnership/ |
Description | Expert panel member on data sharing at World Dementia Council summit - December 2021 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The meeting will have a combination of plenary and parallel sessions on research and care and feature international dementia leaders from across the globe sharing their thinking and work. It will be hybrid although almost all people speaking in each session will be in person. It would be great if you were willing to share your thinking on data sharing. The session will focus on this theme and address questions and themes such as how do we maximise the benefits of big data developing global cohorts, the comparability and sharing of data, and overcoming regulatory barriers? Each speaker will have 7-8 minutes to present and offer introductory remarks. Outcome: Organisers wanted to get in touch with a draft transcript of your contributions to the data sharing session we held at the virtual summit in December. Said it was a great session and we're keen to publish a transcript of this to share with our network. |
Year(s) Of Engagement Activity | 2021 |
URL | https://worlddementiacouncil.org/sites/default/files/2021-12/Programme%20%5Brevised%5D%20-%20WDC%20S... |
Description | Five Lives Health Oxford Industry meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited presentation on multi-modal multi-cohort studies using the DPUK Data Portal |
Year(s) Of Engagement Activity | 2022 |
Description | Fundacio Ace - Barcelona |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | As the director of Dementias Platform UK, Prof John Gallacher was invited to have a meeting with Fundacio Alzheimers Centre Barcelona and DPUK to discuss potential collaboration. |
Year(s) Of Engagement Activity | 2023 |
Description | Genesis Innovation workshop - virtual - 8 Dec 2021 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | Join a panel discussion on access to patient data and translational medicine and the divergence between the EU and the UK's pathways. He thought that you might be better placed to join the discussion as head of DPUK. Following on the conversations with Jan, we have summarized the topics/questions that will be used during the panel discussion on Wednesday 8 December. Please find them below. • Set the stage: o Thanks to new technologies and infrastructures, new frontiers can set using well-organized large patient data systems - have we entered a new era? Are we ready to combine data silos from all over the world into a global data system? o When we talk e.g. about cancer research, inflammation and neurological diseases, how can access to large patient data sets accelerate research in these domains and ultimately improve care? See e.g. single-cell genomics or spatial transcriptomics technologies • Driven by uses/applications: • We hear a lot about patient data, health records, for uses in hospitals, remote monitoring etc o What are the main drivers behind this surge in patient data? Which uses/applications will likely shape the roll out of well-organized patient data systems? o In what way has the current pandemic an effect on this? Did it bring up new innovative ways, did it show a painful shortage in adequate systems? • The current pandemic: o Did it change the access to health records and will it drive the way we handle future health challenges o Did it change or will it change the business model? • Towards a national and international system? o Can we foresee a national (or European) data records system? Is it feasible? Can it be scaled from local to national? o What are the challenges on the level of governance (consent by patients e.g.)? o Can we foresee an optimalization of patient treatments based on patient data outcomes (e.g. best practices, which hospital has the best care for a certain treatment)? • A new business model? o What is the commercial value of data and how is it perceived? o Does this change the balance between payers-care givers-patients? Who pays for these national/international systems and data use? o How can companies jump on the bandwagon and become successful in this new exciting and fast growing domain? |
Year(s) Of Engagement Activity | 2021 |
URL | http://www.genesisconference.com/ |
Description | Great Minds Public Event May 21 - Healthy Aging |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | On line members event with speakers and question time |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.greatmindsfordementia.uk/Join-us/great-minds-member-event-2021 |
Description | Great Minds Public Event Nov 21 - Frontotemporal dementia |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | On 18 November 2021 we brought together leading experts on frontotemporal dementia to explain what the condition is, how it's diagnosed and managed, and how researchers are working towards better treatments. The speakers were Dr Siân Thompson (Consultant Neurologist, John Radcliffe Hospital, Oxford) and Professor James Rowe (Professor of Cognitive Neurology, University of Cambridge). |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.greatmindsfordementia.uk/Join-us/great-minds-members-event-nov-2021 |
Description | Great Minds event: the outlook for new dementia treatments |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Dementias Platform UK - Great Minds is delighted to invite you to its first in-person live event. We've brought together leading figures in dementia diagnosis and treatment to offer a rare, expert-led insight into the latest developments in the field. Topics will include recent advances in our understanding of dementia, emerging treatment options, how new drugs make it to the NHS, and the role technology can play in diagnosis and condition management. Attendees will also have the opportunity to put questions to our experts. The event is aimed at anyone with an interest in dementia and dementia research - no specialist scientific knowledge is required. Prof John Gallacher was invited to give an introduction at the event as an expert in dementias research. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.eventbrite.co.uk/e/great-minds-event-in-person-the-outlook-for-new-dementia-treatments-t... |
Description | Great Minds live event: dementia screening and risk factors |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This is the sixth event for members of DPUK's Great Minds (GM) research volunteer registry - and the second to be held in person. GM members are recruited from cohort studies and via Join Dementia Research, and volunteer to participate in dementia research studies and trials. The aim of the event is to give GM participants added value, and to remind them of the difference volunteers make to medical research and of their commitment to supporting new studies through GM.As Director of DPUK, Prof John Gallacher gave a welcome speech to the event and recent updates on DPUK. |
Year(s) Of Engagement Activity | 2022 |
Description | Great Minds newsletter: April 2021 |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | Newsletter |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.greatmindsfordementia.uk/blog/great-minds-newsletter-april-2021?ref=image |
Description | Great Minds newsletter: January 2022 |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | Newsletter |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.greatmindsfordementia.uk/blog/great-minds-newsletter-january-2022 |
Description | Great Minds newsletter: September 2021 |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Our newsletter |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.greatmindsfordementia.uk/blog/great-minds-autumn-newsletter-2021 |
Description | HDR UK Scientific Conference 2022: Creating trustworthy research environments that enable the greatest benefits for global health and society |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | The conference showcased how health data science can be harnessed to transform global health and society, with a focus on making sure no groups are excluded from these data-driven improvements. Researchers shared learnings from the rapid progress made in health science and data infrastructure as a result of COVID19, to shape the post-pandemic health data science landscape. It brought members of the scientific community, industry and patients and the public together to provide opportunities for collaboration and knowledge sharing. As a Director of Dementias Platform UK, Prof John Gallacher was invited to speak at the conference to set the scene and discuss what are the key ingredients to creating trustworthy research environments that enable the greatest benefits for global health and society. |
Year(s) Of Engagement Activity | 2022 |
Description | HDRUK QQR2 Public Health Research Vision |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | HDRUK QQR2 Public Health Research Vision. HDRUK national meeting, 26/04/21 |
Year(s) Of Engagement Activity | 2021 |
Description | International HundredK+ Consortium (IHCC) Sumit meeting |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited oral presentation: Global Mental Health Impact of Covid-19 project overview |
Year(s) Of Engagement Activity | 2023 |
Description | International HundredK+ Consortium (IHCC) Webinar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited talk on large multi-modal multi-cohort studies on harmonisation in mental health |
Year(s) Of Engagement Activity | 2023 |
Description | Interview for UKDRI news and events |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Spotlight on Prof Valentina Escott-Price |
Year(s) Of Engagement Activity | 2020 |
URL | https://ukdri.ac.uk/news-and-events/spotlight-on-prof-valentina-escott-price |
Description | Invited member of Polygenic Risk Scoring Expert Panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited member of Polygenic Risk Scoring Expert Panel for Illumina company, Batimore, USA |
Year(s) Of Engagement Activity | 2019 |
Description | Invited seminar at Icahn School of Medicine at Mount Sinai |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited seminar at Icahn School of Medicine at Mount Sinai, NY, USA |
Year(s) Of Engagement Activity | 2019 |
Description | Invited seminar talk: Multi-modal cross-cohort research using DPUK Data Portal Geneva University Switzerland |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited seminar talk: Multi-modal cross-cohort research using DPUK Data Portal |
Year(s) Of Engagement Activity | 2022 |
Description | Invited speaker at Alzheimer's Research UK conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker at Alzheimer's Research UK conference, Harrogate UK |
Year(s) Of Engagement Activity | 2019 |
Description | Invited speaker to FBRI Alzheimer's Disease Workshop |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker to FBRI Alzheimer's Disease Workshop, Boston, USA |
Year(s) Of Engagement Activity | 2019 |
Description | Invitee to roundtable - UK DRI's the impact of Aducanumab approval, implications and opportunities - June 2020 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The recent approval of Aducanumab by the FDA as the first therapeutic for Alzheimer's disease in 20 years through accelerated pathway is challenging the field. We will need to rethink the importance of early diagnosis, the role of biomarkers in dementia, patient stratification. It will affect patients' expectations and raises questions on cost/benefit issues for health systems. The UK DRI in collaboration with ARUK is gathering the Dementia UK Ecosystem representatives and other key stakeholders for a virtual roundtable discussion to reflect on the impact of the FDA decision and its implications for the AD field. Outputs: Position paper on opportunities and priorities for the future of AD drug discovery. Depending on the outcome of this initial event we may follow up with other roundtables focussed on specific aspects raised during the discussion. We will keep you informed about these follow-up events. |
Year(s) Of Engagement Activity | 2021 |
Description | Jack FM radio interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Interview regarding my 'Your Beautiful Brain' art workshops for Black African and Caribbean communities |
Year(s) Of Engagement Activity | 2022 |
Description | Janssen Protocol Development |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | This was a meeting to discuss potential collaboration with Janssen Neuroscience as they are preparing for a new phase 2 trial - AD indication/prevention and would like to explore whether we could collaborate/bring the trial to the UK. As this population will be quite challenging to recruit, connecting with existing research cohorts, registries, and global initiatives thinking of UK biobank & DPUK will be key. |
Year(s) Of Engagement Activity | 2022 |
Description | John Gallacher as Chair - A4D conference Arts 4 Brain Health: Social Prescribing as Peri-Diagnostic Practice for Dementia event - May 2021 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | An opportunity for GPs, social prescribers, museums, dance studios, music, drama, arts and health organisations, educationalists and funders, innovative and creative ageing specialists, local authorities and policy makers to come together and revolutionise the world of social prescribing for brain health. Organisers said to John: Thank you for so generously giving your time on Friday and your superb chairing of A4D conference to help advance social prescribing to empower people at the onset of dementia to engage in arts to preserve brain health. Your wisdom and expertise gave the sessions gloriously informed flow. Your guidance was tremendous and it felt as if all were working together on a wave to drive this forward. I am inviting chairs and speakers whom it would interest to sign a group letter to generate interest along these lines: to propose an amendment to the NICE guideline 97 (Published 20 June 2018 www.nice.org.uk/guidance/ng97 1.2 Diagnosis : Initial assessment in non-specialist settings, page 15: It would be of real value if after 1.26 a recommendation could be inserted, advising referral to social prescribing for patient choice of a range of weekly activities to preserve brain health. It would be great if social prescribing, recognised for its transformational effect on the mental health and wellbeing of the nation, were to help reduce loneliness and fear at the onset of dementia, through an adaptation woven into the NICE Diagnosis Guideline at the onset - in line with NICE guidelines for Mental Wellbeing and Independence for Older People? |
Year(s) Of Engagement Activity | 2021 |
URL | https://arts4dementia.org.uk/spconference2021/ |
Description | John Gallacher expert comment - RECON management committee |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | RECON is a research project - Reducing and preventing Cognitive impairment iN older age groups (the RECON programme). It aims to develop and test efficient internet-supported healthy behaviour/cognitive exercises to reduce cognitive decline among older age adults. John Gallacher (as Director of DPUK) provides expert comment to the management committee of the research project. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.southampton.ac.uk/medicine/academic_units/projects/recon.page |
Description | John Gallacher expert comment in Medical News Today article - Dec 2021 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | John provided a key voice amongst other leading experts on a recent study showing that 'Even light-intensity exercise might reduce dementia risk'. NT also spoke with Prof. John Gallacher, director of Dementias Platform UK, at the University of Oxford in the U.K., who was not involved in the study. He agreed with Prof. Matthews, explaining that the findings were significant, but the question of causation was key. "The idea that physical activity reduces the risk of dementia is entirely plausible, and these findings add to a growing body of evidence supporting this idea. The problem is reverse causation - that is, that people with dementia exercise less." Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787226?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121621 - Prof. John Gallacher "This study goes some way to addressing this by looking at incident events and dropping subjects with incident dementia in the first 2 years of follow-up. The dose-response curves are impressive," he continued. Prof. Gallacher said that "[p]ossible mechanisms [for the association] include improved vascular health and improved immunological function. These mechanisms are likely to be interrelated and not independent of each other." |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.medicalnewstoday.com/articles/even-light-intensity-exercise-might-reduce-dementia-risk |
Description | John Gallacher speaker - Challenging times, Changing culture - Oxford, November 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Undergraduate students |
Results and Impact | Building on the experience of Oxford researchers during SARS-CoV-2, this lunchtime seminar will consider the structural context of scientific activity, the strategic impact of collaboration and the lived experience of scientists. John presented on DPUK's collaborative ethos. |
Year(s) Of Engagement Activity | 2021 |
URL | https://talks.ox.ac.uk/talks/id/365773e5-76e1-4d49-ac24-21dee988d961/ |
Description | John as Chair - Launch of Arts 4 Dementia report 'A.R.T.S. for Brain Health - Social Prescribing as Diagnostic Practice for Dementia, Zoom, World Alzheimer's Day - Sept 2021 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | On World Alzheimer's Day, our 'A.R.T.S. for Brain Health' launch coincides the review of Arts 4 Dementia's 2021 social prescribing conference in The Lancet Neurology this month, by Professors John Gallacher and Alistair Burns. |
Year(s) Of Engagement Activity | 2021 |
URL | https://arts4dementia.org.uk/2021/09/a4d-launches-social-prescribing-report-arts-to-preserve-brain-h... |
Description | John presentation - 'Linkages to metrics of the built environment' UK BIOBANK HEALTH-RELATED LINKAGES WORKSHOP - May 2021 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | The aim of the workshop was to assess the scientific value and feasibility of linking to health related (but non-medical) data for the purposes of extending research into social sciences and environmental health. 16.40 - 16.55 Linkages to metrics of the built environment John Gallacher |
Year(s) Of Engagement Activity | 2021 |
Description | John presentation - Rosetrees Interdisciplinary Workshop on neurodegenerative diseases of the brain |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Neurodegenerative diseases in the brain represent a wide range of different underlying pathologies with different clinical sequelae. Therapeutic interventions are currently relatively limited, reflecting the complexity of the diseases. Imaging with different, often combined, modalities (including CT, MRI, PET and SPECT) is a well-established clinical diagnostic tool, whilst imaging at a cellular and molecular level using animal models has also contributed significantly to our understanding of both the detailed anatomical structure and functional behaviour of the brain. Application of advanced statistical techniques and artificial intelligence has accelerated the extraction of detailed and clinically-useful information from images, though combining information from these different techniques across different temporal and spatial scales is challenging. Groups based in physics, mathematics and computational science are increasingly engaged in developing novel tools and techniques which may be applied to the brain and neurodegenerative diseases, including the use of network theory to develop simple models of brain function, applying the understanding of soft matter and polymer physics to the process of protein aggregation, exploring the role of liquid-liquid phase separation in Alzheimer's disease, and developing models of blood flow and mass transport in the brain using computational fluid dynamics. A single workshop in this wide-ranging and developing area will necessarily need to focus on a limited number of particular topics, though it is hoped that in so doing, the value of interdisciplinary approaches to other aspects of the field will be reinforced. The workshop will bring together researchers from the physical, biological and clinical sciences to focus on interdisciplinary approaches to the imaging of neurodegenerative diseases of the brain, including how multiscale imaging information may be combined with other biomarkers in order to better understand and model the extent, nature and impact of neurodegenerative disease. The organiser reported: I just wanted to thank you for making such outstanding contributions to what I hope you will agree was a really stimulating meeting today. The value of working across disciplines was evident with the compelling examples you shared and it was also clear that there are numerous opportunities to build new partnerships in future. I wanted to repeat that we would be very happy to consider applications for follow-on sandpits or w/shops and that the Physics of Life network will also be delighted to signpost the various collaborative platforms and networks. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.physicsoflife.org.uk/neurodegenerative-disease.html |
Description | KCNI External Scientific Advisory Committee - Fall 2022 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | As a Member of the Krembil Centre for Neuroinformatics External Scientific Advisory Committee, Prof John Gallacher has been invited to participate in this meeting. This meeting is schedule to give updates on Krembil Centre for Neuroinformatics and Brain Canada - Youth Platform. |
Year(s) Of Engagement Activity | 2022 |
Description | KCNI External Scientific Advisory Meeting - Spring 2022 |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As the Director of Dementias Platform UK, Prof John Gallacher was invited as an expert on brain health and dementias research. |
Year(s) Of Engagement Activity | 2022 |
Description | Keynote invited speaker, Genetics and epigenetics of mental disorders international conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Keynote invited speaker, Genetics and epigenetics of mental disorders international conference, St Petersburg 2019. |
Year(s) Of Engagement Activity | 2019 |
Description | Keynote speaker at The University of Reading SIAM-IMA student chapter conference |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Undergraduate students |
Results and Impact | Keynote speaker at The University of Reading SIAM-IMA student chapter conference, Reading, UK. |
Year(s) Of Engagement Activity | 2019 |
Description | MRC 10 year Showcase |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Study participants or study members |
Results and Impact | An academic afternoon sharing our latest findings and results of the research undertaken over the last 10 years of the centre. Followed by an evening panel event with Mike, James and Anita chaired by the VC and joined by Robin Buckle of MRC. |
Year(s) Of Engagement Activity | 2019 |
Description | MRC Integrative Epidemiology Unit Mtg 2: Initial Programmatic Assessment |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | John Gallacher has been invited as a committee member to participate in the quinquennial review (QQR) of the MRC Integrative Epidemiology Unit. |
Year(s) Of Engagement Activity | 2022 |
Description | MRC Traumatic Brain Injury platform |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As the Director of Dementias Platform UK, Prof John Gallacher was invited to a meeting with Traumatic Brain Injury platform to discuss future funding for DPUK. |
Year(s) Of Engagement Activity | 2023 |
Description | Meeting Hammersmith Medicines Research (HMR) Limited and DPUK |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | This was a meeting discuss the potential collaboration betweene Hammersmith Medicines Research (HMR) Limited and DPUK. |
Year(s) Of Engagement Activity | 2022 |
Description | Motor Neurone Disease Centre and DPUK potential collaboration |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This was a meeting on the potential collaboration between Motor Neurone Disease centre and Dementias Platform. |
Year(s) Of Engagement Activity | 2022 |
Description | NEURONET Final Consortium Meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | On 1 July, representatives of Neuronet's partner organisations and members of its Scientific Coordination Board (SCB) came together in Barcelona (Spain) to compile and evaluate the achievements of Neuronet at a final meeting. This meeting has also served as an opportunity to share and evaluate lessons learned. |
Year(s) Of Engagement Activity | 2022 |
Description | NEURONET Summit |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | NEURONET has been running since 2019 to provide synergies across the 20+ projects in the current IMI neurodegeneration portfolio (please see www.imi-neuronet.org for more information). The Summit represents a particular ambition: to convene a high-level forum of selected project and opinion leaders to discuss priorities in neurodegeneration research over the next decade. Prof John Gallacher was invited as the Director of Dementias Platform UK and expert in dementias research. |
Year(s) Of Engagement Activity | 2022 |
Description | New DPUK animation |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | To mark the start of the second phase of DPUK, we commissioned a company called SciAni to produce a new animation outlining DPUK's key activities and how they are contributing to efforts to diagnose, treat and prevent dementia. |
Year(s) Of Engagement Activity | 2022 |
URL | https://youtu.be/RAKdHSjTVdE |
Description | New DPUK website |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | In 2021 DPUK's communications team lead the redevelopment of its website to ensure it provided a clear overview of DPUK's activities and would be as useful as possible for key audiences (eg study leaders, ECRs, industry representatives, dementia-interested public etc). Early feedback on the revamp has been positive, and further analysis will be undertaken this year. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.dementiasplatform.uk/ |
Description | PROSPECT study and DPUK |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This was a meeting discussing the potential collaboration between PROSPECT study and DPUK regarding metadata and data access. |
Year(s) Of Engagement Activity | 2022 |
Description | Poster at AAIC Conference July 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Emily Baker, PhD Student (Supervisor - Prof Valentina Escott-Price) Poster at AAIC Conference - July 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | Poster at ASHG Conference - October 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Emily Baker, PhD Student (Supervisor - Prof Valentina Escott-Price) Poster at ASHG Conference - October 2017 |
Year(s) Of Engagement Activity | 2017 |
Description | Presentation at MRI together conference Global workshop on open, reproducible, and inclusive MR research (Dr Gaurav V Bhalerao) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Dr Gaurav V Bhalerao - Presented abstract as first author, "Comparison of automated and manual quality measures for T1w brain MRI scans from clinical population", MRI together conference Global workshop on open, reproducible, and inclusive MR research - 5th - 8th Dec 2022 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.youtube.com/watch?v=OKBk4Jhs4bU |
Description | Presentation to the general public on the DRI program at the DRI launch in Cardiff |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | I have presented on my DRI program "Bioinformatics and Functional genomics" to patients, their families, journalists and other invited guests from the general public at the DRI launch in Cardiff, October 2018. |
Year(s) Of Engagement Activity | 2018 |
Description | Press briefing (SMC/ARUK) - Invited on hearing loss and hearing aid use |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Invited press briefing - modifiable risk factors for dementia - 28 global reporters for international press coverage and BBC |
Year(s) Of Engagement Activity | 2023 |
Description | Press release - IXICO announcing their committed partnership to DPUK as it enters its second phase - Feb 2022 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | IXICO will be an industry member and stakeholder in the DPUK partner forum, working alongside 13 academic partners with expertise in dementia and big data research such as University of Oxford, Cardiff University, University of Cambridge and University of Edinburgh as well as pharma companies active in dementia research such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica NV and Araclon Biotech. IXICO wanted to show they were dedicated to delivering insights in neuroscience. Their purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and their goal is to be a leading proponent of artificial intelligence in medical image analysis. They will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients. |
Year(s) Of Engagement Activity | 2022 |
URL | https://ixico.com/news-and-resources/press-releases/engagement-in-big-data-research-dementia-collabo... |
Description | Press release on dementia and hearing loss paper |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | A press release on a new paper co-funded by DPUK and involving DPUK scientist Dr Sarah Bauermeister was picked up widely in national and local print, online and broadcast media. Highlights included an article in the Sun newspaper (link below). The paper outlined the links between mild cognitive impairment and hearing aid use. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.thesun.co.uk/health/17747984/how-halve-risk-developing-dementia-hearing-aids/ |
Description | Professor John Gallacher LinkedIn profile |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Establishing a LinkedIn profile for John has ensured that DPUK's reach goes wider and reinforces John's influence as a expert and leader in the field of dementia. John has over 300 connections, and had posts related to DPUK receive views of over 700. Older contacts of DPUK have gotten in touch with John to reconnect and investigate collaboration again. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.linkedin.com/in/john-gallacher-phd-afbpss-cpsychol-ffph-b86b08210/ |
Description | Professor John Gallacher Twitter profile - @John_ejg |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Created a social media presence on Twitter for Prof John Gallacher. This has allowed greater reach of DPUK activities and established John as a knowledgeable and respected leader in the field with potential for impact |
Year(s) Of Engagement Activity | 2021 |
URL | https://twitter.com/John_ejg |
Description | Reinvigorating health registries during COVID for rapid policy analyses. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | Reinvigorating health registries during COVID for rapid policy analyses. Norwegian Health Registry Conference, Oslo, 16/11/21. Helse- og Kvalitetsregisterkonferansen 2021 | Keynote presentation. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.registerkonferansen.no/ |
Description | Report/transcript of discussion - World Dementia Council virtual summit 2021 |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Session 1: Data sharing Transcript from the WDC Summit 2021 session looking at data sharing for dementia research, assessing how we can maximise the benefits of big data developing global cohorts, the comparability and sharing of data, and how we can overcome regulatory barriers. |
Year(s) Of Engagement Activity | 2022 |
URL | https://worlddementiacouncil.org/sites/default/files/2022-02/Summit%202021%20-%20Transcript%20-%20Da... |
Description | Roundtable on Motor Neurone Disease (MND) research |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | As the director of Dementias Platform UK, Prof John Gallacher was invited to meet with the Minister of Health on the discussion on Motor Neurone Disease (MND) research. |
Year(s) Of Engagement Activity | 2023 |
Description | SAIL External Advisory Board meeting and Dinner |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This was a meeting for the Scientific External Advisory Board to discuss SAIL Update and Into the Future in preparation for the Board report. |
Year(s) Of Engagement Activity | 2022 |
Description | Scientific Review of the MRC Integrative Epidemiology Unit |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Prof John Gallacher was asked whether they would be willing to serve as a member of the expert Subcommittee for the MRC Population and Systems Medicine Board (PSMB), which will assess the past progress and future proposals of the MRC Integrative Epidemiology Unit (IEU), University of Bristol. The MRC periodically carries out scientific reviews of its Units in order to be assured of: • the overall quality, impact, and productivity (past and future potential) of the Unit's research programmes and the Unit as a whole; • the distinctive contribution of the Unit to MRC's research portfolio, strategic aims and the wider research effort; • the added value from the Unit structure and that this is the most appropriate future form of support to meet MRC's needs; • the appropriateness of resources for the research to be undertaken. |
Year(s) Of Engagement Activity | 2022 |
Description | The DPUK Data Portal and big data analytics |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited oral presentation: The DPUK Data Portal and big data analytics |
Year(s) Of Engagement Activity | 2022 |
Description | The Economist Podcast interview - John Gallacher and his reaction to the FDA's approval of aducanumab to treat Alzheimer's disease - 2021 |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | John was interviewed by The Economist podcast when the FDA granted conditional approval to a drug for the treatment of Alzheimer's disease, called aducanumab. His podcast, and subsequent DPUK subjects broadcasting the piece, garnered strong reaction. It established John and DPUK further as an expert in the dementia field. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.economist.com/podcasts/2021/06/08/a-flicker-of-light-for-the-treatment-of-alzheimers?utm... |
Description | Traumatic Brain Injury platform - Reporter Meeting |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As the Director of \Dementias Platform UK, Prof John Gallacher was invited to join the Traumatic Brain Injury platform Reporter Meeting for the discussion of writing out a grant proposal for DPUK. |
Year(s) Of Engagement Activity | 2023 |
Description | UK Biobank Dementia Group Meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Professor John Gallacher has been invited as an expert of dementias research and discuss how UK Biobank can be more valuable for dementia research. |
Year(s) Of Engagement Activity | 2022 |
Description | UK Biobank Dementia Working Group |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | As Director of Dementias Platform UK, Prof John Gallacher was invited to UK Biobank Dementia Working Group meeting to discuss future Uk Biobank Dementias strategies. |
Year(s) Of Engagement Activity | 2023 |
Description | UK Biobank Scientific Conference 2022 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | UK Biobank hosted this Scientific Conference as a HYBRID event on Tuesday 21st of June 2022. As the world's most comprehensive biomedical database UK Biobank are incredibly proud of the unique scientific discoveries being generated through use of the resource, with thanks to the ongoing commitment of the participants, funders, and the research community. The day included updates of the latest research findings and future ambitions in the areas of genomics, ageing and environmental health research. Professor John Gallacher has been invited to chair a session at the Conference on Transforming Health in Older Age. Prof John Gallacher was invited as the Director of Dementias Platform UK and expert in dementias research. |
Year(s) Of Engagement Activity | 2022 |
Description | UK Biobank Strategic Oversight Committee Meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Professor John Gallacher was invited as a member of the UK Biokbank strategic Oversight Committee and the Director of DPUK. |
Year(s) Of Engagement Activity | 2022 |
Description | UK Biobank Winter Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Prof John Gallacher attended the UK Biobank Winter Scientific Conference as a member of the UK Biobank subcommittee. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.ukbiobank.ac.uk/media/sc5fmgvg/copy-of-winter-conference-twitter-banner-facebook-cover-3... |
Description | UK DRI & DPUK Workshop Experimental models of vascular disease and cognitive impairment |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | This workshop, organised jointly by DPUK and UK DRI, assessed the latest developments in animal models, and their relevance and contribution to the understanding of mechanisms of cerebral microvascular disease in humans. Talks and discussions focused on vascular biology, neurovascular coupling, blood-brain barrier function, and neuroinflammation, as well as issues such as translation and reproducibility. The workshop featured keynote talks from Professor Denis Vivien and Professor Claire Gibson, and roundtable discussion with leaders in the field. Other speakers included Dr Paresh Malhotra, Dr Frances Wiseman and Professor Stuart Allan. One particular aim of the workshop was to increase early-career researcher interest in the field. A dedicated ECR morning session on 17 March focused on how well preclinical models recapitulate the clinical phenotypes. Outputs from the event will include a proceedings paper and the establishment of a number of working groups and grant applications. |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.dementiasplatform.uk/research-hub/experimental-medicine-incubator/vascular-health/vascul... |
Description | UK DRI Dinner at Royal Society |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Dinner at the Royal Society on Wednesday 25thMay 2022, to discuss the institute's innovations with a small group of stakeholders. The evening will include a scientific presentation from the UK DRI's Director, Professor Bart De Strooper. This was a critical time for dementia research. The UK's response to the COVID-19 pandemic has demonstrated the power of our life sciences and health infrastructure, and we have seen extraordinary achievements born of brilliant science and large-scale collaboration. Now is the time to apply this mission-led approach to dementia, which is our greatest - and growing - healthcare challenge. Prof John Gallacher was invited to present on the significant scientific breakthroughs, with the power to transform the dementia research landscape of DPUK. |
Year(s) Of Engagement Activity | 2022 |
Description | Within-person reaction time variability as a measure of the underlying mechanisms shared by dementia and ADHD |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Presented at the AAIC conference on August 1 2022 Authors: Elen Golightly, Emma Squires, Sarah Bauermeister There is evidence that selective neurodevelopmental disorders have numerous neurodiverse symptoms that parallel dementia and cognitive decline, such as executive dysfunction, memory problems and cognitive impairment. These are associated with slower reaction time and increased reaction time variability. However, there is a paucity of research into the effects of ageing, and subsequently, cognitive ageing on the neurodiverse population as many studies focus on early development. Our aim is to highlight the importance of focusing on sub-populations within large cohort datasets as well as using sensitive measures to understand the mechanistic pathways underpinning associations where they exist. In this preliminary study we look in particular at the link of increased within-person reaction time variability (WP RTV) and Attention Deficit Hyperactivity Disorder (ADHD). It is well established that children with neurodevelopmental disorders have increased WP RTV, as do older people experiencing cognitive decline and dementia (e.g., Bauermeister & Bunce, 2015). Our objective is to investigate this measure as a sensitive measure of cognitive change, in comparison to the more commonly focused on reaction time. Method: Using data Brain Health Registry (BHR) (M=58.76, SD13.20 years baseline) we conducted our analysis on the Dementias Platform UK (DPUK) Data Portal. In this preliminary work, we investigate neurodiversity and dementia status and association with reaction time and WP RTV on 19,272 participants using multiple regression. Age and education are included as covariates. We assessed three separate measures of reaction extracted from the Identification test (IDN), the Detection test (DET) and the One-Card Learning (OCL) test. Result: For all three tasks, WP RTV was significantly higher (more variable) in those with dementia, and those with a current diagnosis of ADHD (b=.01; and b=.01 ps<.01) whereas reaction time was significantly slower in only the OCL task in those with dementia, and those with a current diagnosis of ADHD. Conclusion: Our conclusions are that the mechanistic pathways underlying WP RTV may be common across dementia and ADHD, and that WP RTV may be a more sensitive measure of underlying shared mechanisms than reaction time. Our future ongoing work will investigate this in further cohorts across additional tasks. |
Year(s) Of Engagement Activity | 2022 |
URL | https://alz.confex.com/alz/2022/meetingapp.cgi/Paper/67783 |
Description | the UK Pharmacogenetics and Stratified Medicine Network |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited presenter at the UK Pharmacogenetics and Stratified Medicine Network Workshop |
Year(s) Of Engagement Activity | 2021 |